JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Differential ventricular entrainment: a maneuver to differentiate AV node reentrant tachycardia from orthodromic reciprocating tachycardia.

BACKGROUND: Distinguishing atrioventricular node reentry (AVNRT) from orthodromic reentrant tachycardia (ORT) utilizing an accessory pathway (AP) can sometimes be challenging. A pacing maneuver that reliably distinguishes between the two would be of value.

OBJECTIVE: This study sought to assess the utility of differential entrainment for the diagnosis of supraventricular tachycardia.

METHODS: Consecutive patients underwent prospective electrophysiological study of regular paroxysmal supraventricular tachycardia. Overdrive pacing with entrainment of tachycardia from each of the right ventricular apex and right ventricular base was performed. The post-pacing interval (PPI), PPI minus the tachycardia cycle length and corrected for AV node decrement (cPPI-TCL), and the ventriculoatrial (VA) interval (last RV pacing stimulus to last entrained high right atrial signal) were calculated at each site.

RESULTS: Entrainment at both RV sites was achieved in 35 patients, 16 with typical AVNRT, 1 with atypical AVNRT, and 18 with ORT (13 left free wall, 3 right free wall, and 2 septal APs). The cPPI-TCL and VA intervals were significantly longer from base than apex in AVNRT (cPPI-TCL 61 ms longer, VA 38 ms longer, both P < .0001). There was no significant difference in differential entrainment intervals in patients with ORT. A differential cPPI-TCL >30 ms or VA interval >20 ms identified patients with AVNRT with a positive predictive value, negative predictive value, sensitivity, and specificity of 100%.

CONCLUSION: Differential ventricular entrainment is a useful tool for diagnosing between AVNRT and ORT. A differential cPPI-TCL >30 ms or VA interval of >20 ms reliably predicts AVNRT.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app